Nitrofurantoin Dosing for Uncomplicated Cystitis and Prophylaxis
For acute uncomplicated cystitis in adults, use nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days. This regimen achieves 93% clinical efficacy and 88% microbiological efficacy, with minimal resistance development and collateral damage to normal flora 1.
Treatment Dosing for Acute Cystitis
Adults (Women and Men)
- Standard dose: Nitrofurantoin monohydrate/macrocrystals 100 mg orally twice daily for 5 days 1, 2
- Alternative formulation: Nitrofurantoin macrocrystals 50-100 mg four times daily for 5 days 3
- Alternative formulation: Nitrofurantoin macrocrystals prolonged release 100 mg twice daily for 5 days 3
The 5-day regimen is equivalent in efficacy to 7-day courses but with improved tolerability 1. Studies demonstrate that nitrofurantoin 100 mg twice daily for 5 days achieves comparable clinical cure rates (90%) to trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days (90%), with early bacterial cure rates of 92% versus 91% respectively 1.
Pediatric Dosing (>2 months of age)
The evidence does not provide specific pediatric dosing for nitrofurantoin. Guidelines note that shorter courses (3-5 days) are reasonable for cystitis in children when pyelonephritis is unlikely, but specific nitrofurantoin dosing is not detailed 2.
Prophylaxis Dosing for Recurrent UTI
For prophylaxis in adults, use nitrofurantoin 50 mg once daily at bedtime 4. This lower dose is preferred over 100 mg for prophylaxis based on safety considerations.
Key Evidence on Prophylactic Dosing:
- 50 mg daily is the recommended prophylactic dose, typically given at bedtime 4
- A cohort study of 1,893 patients found that 50 mg prophylaxis had equivalent efficacy to 100 mg in preventing UTI (14.8% vs 14.9% developed UTI), but 100 mg was associated with significantly higher rates of adverse events including cough (HR 1.82), dyspnea (HR 2.68), and nausea (HR 2.43) 5
- Alternative schedules include alternate nights, 3 nights per week, or post-intercourse dosing, which are equally effective 4
Important Clinical Considerations
Why Nitrofurantoin is First-Line:
- Minimal resistance: Resistance rates remain low due to multiple mechanisms of action 6, 7
- Minimal collateral damage: High urinary concentration with low serum/tissue levels preserves gut and other microbiomes 6
- Proven efficacy: Clinical cure rates of 88-93% across multiple trials 1
Critical Safety Warnings:
- Avoid in renal impairment: Do not use if creatinine clearance <60 mL/min - inadequate urinary concentrations and increased risk of peripheral neuropathy 8
- Pulmonary toxicity: Chronic use (>6 months) can cause irreversible pulmonary fibrosis; monitor for cough, dyspnea, or malaise 8
- Peripheral neuropathy: Risk increases with renal impairment, diabetes, anemia, vitamin B deficiency - may be irreversible 8
- Hepatotoxicity: Rare but serious hepatic reactions including hepatitis and hepatic necrosis can occur 8
Common Pitfalls to Avoid:
- Don't use for pyelonephritis: Nitrofurantoin achieves inadequate tissue concentrations for upper tract infections 1
- Don't use 100 mg for prophylaxis: The 50 mg dose is safer with equivalent efficacy 5
- Don't prescribe in late pregnancy: Avoid near term due to risk of hemolytic anemia in newborns 3
- Don't use for complicated UTI: Reserved for uncomplicated cystitis only 1
When to Choose Alternatives:
- Local E. coli resistance to nitrofurantoin >20%
- Creatinine clearance <60 mL/min
- Suspected pyelonephritis (use fluoroquinolones or cephalosporins instead)
- Pregnancy near term
- Known G6PD deficiency
The evidence strongly supports nitrofurantoin as first-line therapy due to its sustained effectiveness against common uropathogens, minimal ecological impact, and low resistance rates, making it superior to fluoroquinolones which should be reserved for more serious infections 1, 6.